Investor Ideas #Potcasts #Cannabis News and Stocks on
the Move: Aurora
Cannabis (NYSE: $ACB) (TSX: $ACB.TO), Aphria (TSX; $APHA.TO)(NYSE: $APHA),The
Hill Street Beverage Company (TSXV: $BEER.V) (OTC: $HSEEF), Zenabis Global
(TSXV: $ZENA.V) and Canopy Growth (NYSE: $CGC) (TSX: $WEED.TO)
Delta,
Kelowna, BC –March 4, 2019 (Investorideas.com Newswire) www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s edition
of Investorideas.com potcastsCM - cannabis
news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good
afternoon and welcome to another Investorideas.com “potcast”, looking at
cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Let’s
start with the easy news of Aurora Cannabis Inc. announcing that the Company has completed the
acquisition of all the issued and outstanding shares of privately held Whistler
Medical Marijuana Corporation, in an all-share transaction, pursuant to the
terms of an amalgamation agreement dated January 31, 2019 among Whistler,
Aurora, and a wholly owned subsidiary of Aurora.
Whistler
has developed one of Canada's most iconic cannabis brands, built on quality,
award-winning, organic certified BC bud and the transaction provides Aurora
with a premium and differentiated organic certified product suite, expanding
both its medical and consumer offerings, and reinforcing Aurora's presence in
the well-established west coast cannabis market.
"Now
that this transaction is complete, we intend to accelerate development of
Whistler and leverage its iconic brand globally," said Terry Booth, CEO of
Aurora. "Applying certain of our best practices to the Whistler cultivation
protocols, we anticipate an increase in capacity of the Pemberton facility
beyond the stated 5,000 kg annual production target. Furthermore, in pursuing
EU GMP certification, we expect, once certified, to offer Whistler's premium
organic flower and derivative products in the much higher margin EU medical
cannabis market, further increasing the accretive nature of this transaction.
Whistler and Aurora are very much aligned with respect to cannabis culture and
community. We expect a swift and successful integration with Whistler, our
latest partner."
Aurora
has had a busy month. having announced the first commercial export of cannabis
oil to the United Kingdom, the
Company's
construction of a 300,000 square foot expansion at
the Edmonton International Airport, named Aurora Polaris, intended to serve as
Aurora's centre of excellence for the industrial-scale production of higher
margin, as well ast it has agreed to terms to acquire
a 51% ownership interest in Gaia Pharm Lda., a license
applicant in Portugal, to establish a local facility to produce medical
cannabis and derivative products.
Aphria Inc. announced that
Health Canada has granted the Company its license amendment, permitting Aphria
to commence production in an additional 800,000 square feet of facilities at
its Aphria One location, as part of the Company's completed Part IV and Part V
expansions.
"This is a major milestone for
Aphria on its path to becoming a leading global cannabis producer, as well as a
positive development greatly anticipated by the Canadian cannabis
industry," said Irwin D. Simon, Interim CEO of Aphria. "Aphria's
progress expanding production and automation is essential to our strategy of securing
scale and long-term advantages that enable the evolution of the cannabis
industry through product and brand innovation. With Aphria One, we now have the
ability to expand our production capacity by over three times."
Simon concluded, "We are ready to
hit the ground running and look forward to alleviating industry-wide supply
constraints with our greatly expanded production capacity and sophisticated,
proprietary automation technology that will ensure Aphria remains at the
forefront of cannabis cultivation and innovation. In anticipation of Health
Canada's approval, we had allocated a portion of our previously approved
capacity to mother and vegetative plants that will be used as the initial
growing crops in Part IV and Part V. As a result of these measures, growing
operations in the expanded facilities are expected to commence without delay.
By this Friday, we will move swiftly to establish nearly 22,000 plants in the
Part IV and Part V expansion, with an additional 12,000 plants added each week
thereafter until we reach full crop rotation."
This follows Aphria Inc.’s announcement in
February of a worldwide license agreement with Manna Molecular Science, LLC, as
well as the independent members of its Board of Directors
consisting of Shlomo Bibas, John Herhalt, Tom Looney and Irwin Simon, who
unanimously approved the early termination and liquidation of a promissory
note, option and other agreements related to the Company's previously announced
divestment of all interests in Liberty Health Sciences, Inc.
As detailed on September 6, 2018, the
Company entered into a share purchase agreement with a group of buyers, wherein
it completed the sale of the shares making up 100% of its outstanding interest
in Liberty, in exchange for a five-year promissory note due September 6, 2023,
bearing interest at 12% per annum and in the amount of $59,097,986. Aphria
retained an irrevocable option to repurchase its shares in Liberty from the
buyers for a period of up to five years, subject to the satisfaction of certain
conditions.
In line with Aphria's commitment to
enhanced corporate governance practices and a renewed focus on its strategic
plan, the option in the Liberty shares represented a non-essential holding of
the Company. Accordingly, the independent members of the Board of Directors
unanimously approved the Early Termination
and Liquidation wherein the
Company received cash consideration of $47.4 million and may earn
up to an additional $10 million based on certain value thresholds, if the
counterparties monetize the Liberty shares underlying the terminated option
within six months. Jefferies LLC acted as financial advisor to the Company.
The Hill Street Beverage Company challenged
Canadians to go alcohol-free for the month of January, and in doing so
demonstrated its ability to leverage effective marketing to achieve its
business objectives.
The "Hill Street Challenge"
represented the Company's first fully-integrated marketing campaign, and
capitalized on a growing trend to go "dry" for the month of January.
It was designed to build awareness of the Hill Street brand amongst Canadians,
help people understand the benefits of going alcohol-free, and ultimately drive
consideration of the company's alcohol-free products.
"We created the Hill Street
Challenge as a way to highlight some benefits of going alcohol-free, but
decided to do that in a slightly outrageous way so people would sit-up and take
notice" said David Pullara, Chief Marketing Officer at Hill Street,
referring to the irreverent videos created as part of the campaign. "We've
been working hard over the past year to get people to understand that giving up
alcohol doesn't mean giving up drinking or even having a good time, and the outstanding
results of this campaign demonstrate our efforts are having an impact."
Zenabis Global Inc. announced that it has been approved to
cultivate and grow cannabis at its 255,000 square foot facility in Stellarton,
Nova Scotia. This represents the third Zenabis facility in Canada licensed to
grow cannabis, adding design capacity of 18,500 kilograms of dried cannabis per
year.
This follows Zenabis announcing
reaching a letter of intent with the Société
québécoise du cannabis (SQDC). Quebec is the ninth Canadian jurisdiction in
which Zenabis has a distribution relationship. Zenabis also has distribution
arrangements with government and third-party retailers/distributors in British
Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince
Edward Island, and the Yukon Territory.
Lastly we look at Canopy Growth
Corporation who
announced a transformative clinical research
partnership that will investigate the efficacy of cannabinoids as an integral
part of a novel treatment for post-concussion neurological diseases in former
NHL players.
Researchers estimate that between 1.6 and
3.8 million athletes suffer from a sports-related concussion each year*. Ten to
15 percent of these athletes will go on to develop chronic post-concussion
symptoms that can affect their ability to function. The results of this
original study may also lead to new cannabinoid-based therapies that help
athletes in other professional sports, along with adults who suffer from the
aftermath of brain injuries from accidents and other activities.
Approximately 100 former players will be
enrolled in this randomized double-blind study. The research will be led by
NEEKA Health Canada's Dr. Amin Kassam, a world-renowned neurosurgeon who
completed his undergraduate training at the University of Toronto and has led
four neurosurgery programs over two decades. Joining Dr. Kassam is Dr. Richard
Rovin, a neurosurgeon who completed post-graduate training through the Global
Clinical Scholars Research Training Program at Harvard University Medical
School. Their combined expertise in neuroscience, molecular cell signaling,
brain mapping, and clinical trial design may lead to novel cannabis therapies
that have the potential to improve the lives of patients suffering from
post-concussion healthcare issues.
As the cannabis industry continues to
grow Investorideas.com “potcasts” will continue to deliver more ideas worth
investing in.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the
Investorideas.com website
and this podcast is not an endorsement to buy products or services or
securities. Investors are reminded all investment involves risk and possible
loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an
Investor ideas member , plus get weekly updates with new pot stocks added and
get the daily potcast for Investor Ideas #Potcasts
#Cannabis News and Stocks on the Move.
Learn more https://www.investorideas.com/membership/
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news and press releases plus
we create original financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts
and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto
Corner and Podcast, Play by Play sports and stock
news column, Investor
Ideas #Potcasts #Cannabis News and Stocks
on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast
and column covering developments in AI.
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact each
company directly regarding content and press release questions. Disclosure is
posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers.
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with Sedar.
Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Investor Ideas does
not condone the use of cannabis except where permissible by law. Our site does
not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
